Profile data is unavailable for this security.
About the company
DocMorris AG, formerly Zur Rose Group AG, is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. DocMorris operates at the healthcare, technology and e-commerce, with a primary focus on customer-centric digital healthcare and improving medication efficacy. core business is online pharmacy. In addition to prescription medicines (Rx), assortment features over-the-counter (OTC) and consumer health as well as beauty and personal care (BPC) products. Private labels, including nutritional supplements, painkillers, first-aid products and other OTC medicines. The Company's operates under brands such as PromoFarma, DoctiPharma, Apotal, Medpex and Teleclinic, among others
- Revenue in CHF (TTM)1.06bn
- Net income in CHF-120.87m
- Incorporated1993
- Employees1.45k
- LocationDocMorris AGWalzmuehlestrasse 49FRAUENFELD 8500SwitzerlandCHE
- Phone+41 527240020
- Fax+41 527240015
- Websitehttps://corporate.docmorris.com/en/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EQL Pharma AB | 36.92m | 2.54m | 165.66m | 23.00 | 65.22 | 7.08 | -- | 4.49 | 0.992 | 0.992 | 14.38 | 9.14 | 0.6682 | 1.39 | 5.93 | 20,273,860.00 | 4.60 | 8.85 | 6.61 | 14.41 | 41.19 | 35.90 | 6.89 | 9.33 | 1.03 | 2.25 | 0.6183 | -- | 41.39 | 38.98 | 89.93 | 73.96 | 69.45 | -- |
| DocMorris AG | 1.06bn | -120.87m | 291.90m | 1.45k | -- | 0.5651 | -- | 0.2748 | -4.58 | -4.58 | 41.28 | 10.01 | 1.17 | 18.99 | 19.96 | 730,561.90 | -13.26 | -13.84 | -15.87 | -16.82 | 21.68 | 17.89 | -11.38 | -12.21 | 2.85 | -3.40 | 0.4001 | -- | 4.91 | -5.58 | 17.28 | -- | -7.17 | -- |
| Apotea AB (publ) | 624.58m | 19.83m | 519.77m | 727.00 | 26.24 | -- | 15.42 | 0.8322 | 2.19 | 2.19 | 69.14 | -- | -- | -- | -- | 9,908,253.00 | -- | -- | -- | -- | 13.63 | -- | 3.14 | -- | -- | 35.93 | -- | -- | 10.12 | -- | 6.42 | -- | -- | -- |
| Redcare Pharmacy NV | 2.58bn | -32.23m | 1.25bn | 2.66k | -- | 2.69 | 41.90 | 0.4844 | -1.80 | -1.80 | 140.67 | 24.69 | 2.52 | 13.88 | 24.77 | 1,060,867.00 | -3.25 | -5.98 | -4.64 | -7.43 | 22.88 | 24.37 | -1.29 | -3.06 | 1.23 | -3.88 | 0.4291 | -- | 31.79 | 27.59 | -277.58 | -- | 23.38 | -- |
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 21 Nov 2025 | 5.01m | 9.81% |
| Z�rcher Kantonalbank (Investment Management)as of 15 Jan 2026 | 2.52m | 4.94% |
| Astaris Capital Management LLPas of 22 Jan 2026 | 2.38m | 4.65% |
| NS Partners Europe SAas of 12 Dec 2025 | 1.65m | 3.24% |
| Norges Bank Investment Managementas of 15 Jan 2026 | 1.53m | 2.99% |
| FundSight SAas of 25 Mar 2025 | 900.81k | 1.76% |
| PSquared Asset Management AGas of 17 Sep 2024 | 781.64k | 1.53% |
| Sands Capital Management LLCas of 31 Dec 2024 | 772.77k | 1.51% |
| LLB Invest Kapitalanlagegesellschaft mbHas of 30 Jun 2025 | 310.77k | 0.61% |
| UBS Asset Management (UK) Ltd.as of 29 Aug 2025 | 190.22k | 0.37% |
